Mark Munger, PharmD, discusses recent study findings, which show that ranolazine increases the adverse effect profile of angiotensin-converting enzyme inhibitors and angiotensin receptor blockers, raising concern for patient safety.
In part 2 of this series, Mark Munger, PharmD, explains why the consequences of PBM practices on community pharmacy have wide implications to society, the profession, and the US health care system overall.
In this 3-part series, Mark Munger, PharmD, highlights the impact pharmacy benefit managers have on community pharmacies. In part 1, Dr Munger provides details on why he believes PBMs are directly or indirectly contributing to the closure of community pharmacies.
Mark Munger, PharmD, explains why the phenotypic presentation of heart failure must be studied and highlights why he believes new therapeutic targets are needed based on the changing heart failure phenotype.